BRCA2 and breast carcinoma: We therefore interrogated the whole-genome sequencing data from 560 breast cancers (Nik-Zainal et al., 2016) to determine the rearrangement frequency at the genomic loci that require MiDAS repair upon BRCA2 abrogation or aphidicolin treatment (Figure 1C).